5 Best Immunotherapy Stocks To Buy Now

4. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 73

Pfizer Inc. (NYSE:PFE), a multinational pharmaceutical and biotechnology company based in New York City, is renowned for its contributions to various medical fields, including immunology, oncology, cardiology, endocrinology, and neurology. In 2022, Pfizer’s standout product was the COVID-19 vaccine Comirnaty, which generated $37.8 billion in alliance revenues and direct sales.

Pfizer has received FDA approval for its vaccine, Penbraya, which protects against five categories of life-threatening bacteria that can lead to conditions such as meningitis and blood poisoning. The company presently offers two vaccines to prevent this disease.

As of the end of Q2 2023, 73 hedge funds in Insider Monkey’s database maintained stakes in Pfizer Inc. (NYSE:PFE), with a combined value exceeding $1.5 billion. Leading the pack in Q2 was Diamond Hill Capital, which held approximately 7 million shares of the company.

Diamond Hill Large Cap Strategy made the following comment about Pfizer Inc. (NYSE:PFE) in its Q2 2023 investor letter:

“Our bottom contributors in Q2 included health insurance company Humana, biopharmaceutical company Pfizer Inc. (NYSE:PFE) and global entertainment company Disney. Pharmaceutical giant Pfizer has been dealing with a decline in sales due to lower COVID vaccination levels. Additionally, in 2023, management is increasing spend as the company invests in new product launches. That said, we remain positive about the long-term company fundamentals.”